[go: up one dir, main page]

WO2012107890A3 - Crystal forms of lurasidone chlorhydrate - Google Patents

Crystal forms of lurasidone chlorhydrate Download PDF

Info

Publication number
WO2012107890A3
WO2012107890A3 PCT/IB2012/050573 IB2012050573W WO2012107890A3 WO 2012107890 A3 WO2012107890 A3 WO 2012107890A3 IB 2012050573 W IB2012050573 W IB 2012050573W WO 2012107890 A3 WO2012107890 A3 WO 2012107890A3
Authority
WO
WIPO (PCT)
Prior art keywords
lurasidone
chlorhydrate
crystal forms
schizophrenia
processes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2012/050573
Other languages
French (fr)
Other versions
WO2012107890A2 (en
Inventor
Suresh Babu Jayachandra
Tarun Kumar SINGH
Udaibhan Singh GAHLOT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of WO2012107890A2 publication Critical patent/WO2012107890A2/en
Publication of WO2012107890A3 publication Critical patent/WO2012107890A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides crystalline forms of lurasidone hydrochloride, processes for their preparation, pharmaceutical compositions comprising them and their use for the treatment of schizophrenia.
PCT/IB2012/050573 2011-02-10 2012-02-08 Crystalline forms of lurasidone hydrochloride Ceased WO2012107890A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN340/DEL/2011 2011-02-10
IN340DE2011 2011-02-10

Publications (2)

Publication Number Publication Date
WO2012107890A2 WO2012107890A2 (en) 2012-08-16
WO2012107890A3 true WO2012107890A3 (en) 2012-11-01

Family

ID=46639005

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/050573 Ceased WO2012107890A2 (en) 2011-02-10 2012-02-08 Crystalline forms of lurasidone hydrochloride

Country Status (1)

Country Link
WO (1) WO2012107890A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013030722A1 (en) * 2011-08-26 2013-03-07 Ranbaxy Laboratories Limited Crystalline lurasidone hydrochloride
WO2013121440A1 (en) 2012-02-13 2013-08-22 Cadila Healthcare Limited Process for preparing benzisothiazol-3-yl-peperazin-l-yl-methyl-cyclo hexyl-methanisoindol-1,3-dione and its intermediates
CN102863437A (en) * 2012-09-04 2013-01-09 济南百诺医药科技开发有限公司 Preparation method of lurasidone
WO2014064714A2 (en) * 2012-10-22 2014-05-01 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of lurasidone hydrochloride
CN102911170A (en) * 2012-11-15 2013-02-06 苏州第壹制药有限公司 Method for preparing imide compound hydrochloride
WO2014102834A2 (en) * 2012-12-31 2014-07-03 Hetero Research Foundation Process for lurasidone
CN105524057A (en) * 2013-03-06 2016-04-27 江苏恩华药业股份有限公司 Lurasidone hydrochloride new crystal form and preparation method thereof
JP6594351B2 (en) 2014-06-16 2019-10-23 ジョンソン、マッセイ、パブリック、リミテッド、カンパニー Process for producing alkylated arylpiperazine and alkylated arylpiperidine compounds containing novel intermediates
US10987303B2 (en) 2018-05-02 2021-04-27 LifeMax Laboratories, Inc. Extended release suspension formulation of lurasidone

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0464846A1 (en) * 1990-07-06 1992-01-08 Sumitomo Pharmaceuticals Company, Limited Imide derivatives, and their production and use
EP1327440A1 (en) * 2000-09-22 2003-07-16 Sumitomo Pharmaceuticals Company, Limited Oral preparations with favorable disintegration characteristics
EP1652848A1 (en) * 2003-07-29 2006-05-03 Dainippon Sumitomo Pharma Co., Ltd. Process for producing imide compound
EP1884242A1 (en) * 2005-05-26 2008-02-06 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical composition
EP1891956A1 (en) * 2005-06-13 2008-02-27 Dainippon Sumitomo Pharma Co., Ltd. Solubilization preparation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0464846A1 (en) * 1990-07-06 1992-01-08 Sumitomo Pharmaceuticals Company, Limited Imide derivatives, and their production and use
EP1327440A1 (en) * 2000-09-22 2003-07-16 Sumitomo Pharmaceuticals Company, Limited Oral preparations with favorable disintegration characteristics
EP1652848A1 (en) * 2003-07-29 2006-05-03 Dainippon Sumitomo Pharma Co., Ltd. Process for producing imide compound
EP1884242A1 (en) * 2005-05-26 2008-02-06 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical composition
EP1891956A1 (en) * 2005-06-13 2008-02-27 Dainippon Sumitomo Pharma Co., Ltd. Solubilization preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
COLE, P. ET AL: "Lurasidone hydrochloride : dopamine D2/5-HT2A antagonist treatment of schizophrenia", DRUGS OF THE FUTURE, vol. 33, no. 4, 2008, pages 316 - 322, XP002681381 *

Also Published As

Publication number Publication date
WO2012107890A2 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
WO2012107890A3 (en) Crystal forms of lurasidone chlorhydrate
HUE040307T2 (en) New oxintomodulin derivatives and pharmaceutical compositions containing them for the treatment of obesity
IL230830A0 (en) Cellular compositions for the treatment of retinal degeneration diseases
WO2012068441A3 (en) Intedanib salts and solid state forms thereof
HUE037747T2 (en) Nanostructured aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them
HK1206028A1 (en) Phenicol antibacterials
WO2012070062A3 (en) Novel polymorph of nilotinib hydrochloride
WO2013004995A8 (en) Pyrimidinone compounds and their use
PL2429507T3 (en) Phosphate-free pharmaceutical composition for the treatment of glaucoma
WO2014076712A3 (en) Lurasidone hydrochloride solid dispersion
MX2014010433A (en) Novel crystalline form of sitagliptin sulfate.
EP2583969A4 (en) Novel rhodanine derivatives, method for preparing same, and pharmaceutical composition for the prevention or treatment of aids containing the rhodanine derivatives as active ingredients
EP2736905A4 (en) Intermediate compounds and process for the preparation of lurasidone and salts thereof
IL209360A (en) Pharmaceutical compositions comprising pm00104 for the treatment of multiple myeloma
IL232058A0 (en) Processes for the preparation of 6 - chloro - 2, 3, 4, 9 - tetrahydro - 1h - carbazole - 1 - carboxamide and of its precursors
IL225105A (en) Heterocyclic compounds, process for their preparation, pharmaceutical compositions comprising them and use thereof for the preparation of medicaments
ECSP13012459A (en) HIGHLY CRYSTAL VALSARTAN
AP2012006280A0 (en) Synthesis process, and crystalline form of 4-ä3-ÄCis-hexahydrocyclopentaÄCÜpyrrol-2(1H)-YLÜpropoxyübenzamide hydrochloride and pharmaceutical compositions containing it.
SI2662382T1 (en) Sterol derivatives, method for preparing same, pharmaceutical compositions containing same and use thereof for the treatment of multiple glioblastomas
IN2015DN02109A (en)
WO2011095985A3 (en) Rasagiline salts and processes for the preparation thereof
WO2012038971A3 (en) Novel polymorphs of febuxostat
WO2013114397A3 (en) Pharmaceutically acceptable salt of brinzolamide and composition thereof
EP2529728A4 (en) Pharmaceutical compositions for the treatment of bacterial infections
WO2014174529A3 (en) Polymorphs of avanafil

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12704445

Country of ref document: EP

Kind code of ref document: A2